
CLAIMS

1. A pharmaceutical composition comprising:

a compound represented by formula 1:

[Formula 1]



or a salt thereof or a solvate of these and a lubricant;

wherein the compound represented by formula I or a salt thereof or a solvate of these is a p-toluenesulfonate of the compound represented by formula l; and

wherein a volume based particle size of the p-toluenesulfonate of the compound represented by formula l has d_{10} of less than 5.76 μm, d_{50} of less than 8.81 μm, d_{90} of less than 13.08 μm.

2. The pharmaceutical composition according to claim 1, further comprising an excipient and a disintegrant.

3. The pharmaceutical composition according to claim 1 or 2, wherein a content of the lubricant is 0.5 wt% or more based on a total of the pharmaceutical composition.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein a content of the excipient is 25 wt% or more based on the total of the pharmaceutical composition.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein a content of the disintegrant is 10 wt% or more based on the total of the pharmaceutical composition.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein, as

the lubricant, at least one lubricant selected from the group consisting of sodium stearyl fumarate, zinc stearate, aluminum stearate, calcium stearate, magnesium stearate, talc, and a sucrose fatty acid ester is contained.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein, as the excipient, at least one excipient selected from the group consisting of mannitol, lactose hydrate, fructose, glucose, sorbitol, corn starch, potato starch, wheat starch, and rice starch is contained.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein, as the disintegrant, at least one disintegrant selected from the group consisting of croscarmellose sodium, carmellose sodium, hydroxypropyl cellulose, carmellose, carmellose calcium, methylcellulose, crystalline cellulose, sodium lauryl sulfate, povidone, and polysorbate is contained.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein a content of the compound represented by formula 1 or a salt thereof or a solvate of these is in a range of 5 wt% or more and 50 wt% or less based on the total of the pharmaceutical composition.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the p-toluenesulfonate of the compound represented by formula 1 is a type 1 crystal.

11. A pharmaceutical formulation comprising the pharmaceutical composition according to any one of claims 1 to 10.

12. The pharmaceutical formulation according to claim 11, wherein the pharmaceutical formulation is selected from the group consisting of a powdered formulation, a powder, a granule, a tablet, and a capsule.

13. The pharmaceutical formulation according to claim 11 or 12, wherein the pharmaceutical formulation is a capsule.

14. The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is in a form of a capsule containing a p-toluenesulfonate of the compound represented by formula 1, which is an active ingredient, as a type 1 crystal, and further containing mannitol, croscarmellose sodium, and sodium stearyl fumarate.